Zollinger‑Ellison Syndrome (ZES): A Complete Patient Guide

Overview

Zollinger‑Ellison syndrome (ZES) is a rare disorder in which one or more tumors—called gastrinomas—form in the pancreas or duodenum. These tumors secrete excessive amounts of the hormone gastrin, leading to markedly increased gastric acid production. The resulting hyperacidity causes severe peptic ulcers, diarrhea, and malabsorption.

Who it affects: ZES can occur at any age but most commonly presents in adults between 30 and 60 years. Both men and women are affected, though some studies suggest a slight male predominance (≈55 %).

Prevalence: Gastrinomas are uncommon, occurring in about 1–3 cases per million people per year. Approximately 20–30 % of gastrinomas are associated with the inherited condition multiple endocrine neoplasia type 1 (MEN‑1) ^[1][2]. Sporadic (non‑inherited) ZES accounts for the remaining 70–80 %.

Symptoms

Symptoms result from chronic gastric acid excess and tumor growth. Not every patient experiences all of them.

• Abdominal pain – usually epigastric, worsening 1–3 hours after meals.
• Peptic ulcers – multiple, often refractory to standard therapy; can occur in the duodenum, jejunum, or even the colon.
• Diarrhea – watery, sometimes greasy; caused by acid inactivation of pancreatic enzymes.
• Steatorrhea (fatty stools) – a sign of malabsorption.
• Heartburn/GERD – due to acid reflux.
• Nausea and vomiting – especially after large meals.
• Weight loss – secondary to malabsorption and reduced intake.
• Gastrointestinal bleeding – melena or hematemesis from ulcer erosion.
• Gastric outlet obstruction – rare, caused by ulcer scarring.
• Fatigue – from anemia or nutrient deficiencies.
• Skin changes – if associated with MEN‑1 (e.g., facial angiofibromas, hyperpigmented lesions).

Causes and Risk Factors

Primary cause

ZES is caused by gastrin‑producing neuroendocrine tumors (gastrinomas). These tumors are usually well‑differentiated and arise in:

• Duodenum (≈60 % of cases)
• Pancreas (≈25 %)
• Rarely, other parts of the gastrointestinal tract or lymph nodes.

Genetic risk factors

• Multiple endocrine neoplasia type 1 (MEN‑1) – an autosomal‑dominant mutation in the MEN1 tumor‑suppressor gene. Up to 30 % of ZES patients have MEN‑1.
• Familial Zollinger‑Ellison syndrome – rare inherited gastrinoma without other MEN‑1 features.

Other risk factors

• Age > 30 years (median diagnosis age ≈ 45 years)
• Male sex (slight predominance)
• Family history of MEN‑1 or gastrinoma

There are no known lifestyle or environmental triggers that cause sporadic gastrinomas.

Diagnosis

Diagnosing ZES involves confirming hypergastrinemia, ruling out other causes of high gastrin, and locating the gastrinoma.

Initial laboratory evaluation

• Fasting serum gastrin level – a level > 1000 pg/mL (or > 10‑times the upper limit) strongly suggests ZES, especially when gastric pH < 2.0. Levels between 150‑1000 pg/mL require further testing.
• Secretin stimulation test – intravenous secretin normally suppresses gastrin; in ZES it paradoxically raises gastrin > 120 pg/mL.
• Basic metabolic panel, CBC, and vitamin B12/iron studies to assess for malabsorption.

Imaging studies

• Endoscopic ultrasound (EUS) – high sensitivity (≈80 %) for small duodenal/pancreatic lesions.
• Multiphasic contrast‑enhanced CT or MRI – preferred for staging and detecting metastatic disease.
• Somatostatin receptor scintigraphy (Octreoscan) or ^68Ga‑DOTATATE PET/CT – most sensitive for neuroendocrine tumor localization, especially when conventional imaging is negative.

Other procedures

• Upper endoscopy (EGD) – identifies ulcers, obtains biopsies to exclude H. pylori or malignancy.
• Selective arterial secretin stimulation test – performed in specialized centers to map gastrin production to specific vascular territories.

Diagnostic criteria summary

1. Fasting gastrin > 1000 pg/mL with gastric pH < 2, or
2. Fasting gastrin > 150 pg/mL plus a positive secretin stimulation test, and
3. Radiologic or functional imaging confirming a gastrinoma.

Treatment Options

Management targets two goals: control gastric acidity and eradicate or control the tumor.

Acid‑suppression therapy

• Proton pump inhibitors (PPIs) – high‑dose (e.g., omeprazole 60‑80 mg/day or equivalent) are first‑line. Doses may need titration based on symptom control and gastrin levels.
• Histamine‑2 receptor antagonists (H2 blockers) – less effective alone but can be added for breakthrough symptoms.

Surgical treatment

• Curative resection – indicated for localized gastrinomas without metastasis. Surgical approaches include enucleation, pancreaticoduodenectomy, or duodenal excision, depending on tumor size and location.
• Debulking surgery – for metastatic disease when > 90 % of tumor burden can be removed, improving symptom control.

Medical therapies for tumor control

• Somatostatin analogues (octreotide, lanreotide) – bind somatostatin receptors, suppress gastrin secretion and may stabilize tumor growth.
• Targeted therapy – everolimus (mTOR inhibitor) or sunitinib (tyrosine‑kinase inhibitor) for progressive, unresectable neuroendocrine tumors.
• Chemotherapy – rarely used; reserved for high‑grade neuroendocrine carcinoma.

Other interventions

• Peptide receptor radionuclide therapy (PRRT) – ^177Lu‑DOTATATE delivers radiation directly to somatostatin‑receptor‑positive tumors; shown to improve progression‑free survival.
• Radiofrequency ablation or embolization – for liver metastases.

Lifestyle and supportive measures

• Small, frequent meals; avoid large fatty meals that stimulate acid.
• Limit alcohol, caffeine, and smoking, which increase gastric secretion.
• Supplement fat‑soluble vitamins (A, D, E, K) and B12 if malabsorption is present.
• Regular bone‑density screening – chronic hyperacidity can lead to osteoporosis.

Living with Zollinger‑Ellison Syndrome

Daily management tips

1. Medication adherence – take PPIs exactly as prescribed; never skip doses.
2. Monitor symptoms – keep a log of pain, stool consistency, and any bleeding.
3. Nutrition – work with a dietitian to ensure adequate caloric intake and nutrient absorption.
4. Regular follow‑up – serum gastrin and imaging every 6–12 months, or sooner if symptoms change.
5. Vaccinations – consider hepatitis B and yearly influenza; immunosuppressive therapies (e.g., everolimus) increase infection risk.

Psychosocial support

Living with a chronic, rare disease can be stressful. Seek counseling, join support groups (e.g., NEC Foundation), and involve family in care planning.

Prevention

Because ZES is usually caused by sporadic tumor development, primary prevention is limited. However, you can reduce risk or detect disease earlier:

• For individuals with MEN‑1 or a family history of gastrinomas, undergo genetic counseling and periodic screening (annual fasting gastrin, imaging).
• Eradicate Helicobacter pylori infection promptly; while it does not cause ZES, it can exacerbate ulcer disease.
• Maintain a healthy lifestyle—balanced diet, avoiding tobacco and excessive alcohol—to support overall gastrointestinal health.

Complications

If untreated or inadequately controlled, ZES can lead to serious health problems:

• Refractory peptic ulcers – may perforate, cause peritonitis, or bleed massively.
• Gastrointestinal bleeding – requires transfusion or endoscopic intervention.
• Malabsorption & nutritional deficiencies – leading to anemia, osteoporosis, and weight loss.
• Gastric outlet obstruction – from ulcer scarring.
• Liver metastases – occur in ~30–40 % of patients at diagnosis; can cause hepatic dysfunction.
• Carcinoid syndrome – rare, but neuroendocrine tumors can produce other hormones.
• Reduced quality of life & psychological distress due to chronic pain and medication burden.

When to Seek Emergency Care

References

1. National Institute of Diabetes and Digestive and Kidney Diseases. Zollinger‑Ellison Syndrome. Updated 2023.
2. Mayo Clinic. Zollinger‑Ellison syndrome. Accessed May 2024.
3. Halfdanarson TR, et al. “Pancreatic Neuroendocrine Tumors.” Annals of Oncology. 2022;33(5): 476‑485.
4. World Health Organization. Neuroendocrine Tumors Fact Sheet. 2022.
5. Cleveland Clinic. Zollinger‑Ellison Syndrome. Reviewed 2023.
6. European Neuroendocrine Tumor Society (ENETS) Guidelines. “Management of Gastrinomas.” 2021.